Cancer Forums and News by PhD's


News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
liver
New ablation technique holds promise for liver cancer patients
By Dross at 2013-04-18 21:55
 

A new minimally invasive tumor ablation technique is providing hope for liver cancer patients who can't undergo surgery or thermal ablation, a study shows.

The study of 22 patients at the Universitatsklinikum Regensberg in Regensberg, Germany, found that irreversible electroporation (IRE) successfully destroyed tumor tissue in 70% of these patients.

read more | 2 comments | 3536 reads

Stem cell research aids understanding of cancer
By Dross at 2012-07-20 20:25
 

The study, published in the journal Stem Cell, adds to our understanding of the role of stem and next stage progenitor cells in tissue regeneration and in the diagnosis and treatment of cancer. While stem cells are known to reside in organs such as the liver and pancreas, they are difficult to isolate. The new findings show that an antibody developed by the team can be used to capture the stem cells.

read more | 5 comments | 3922 reads

Scientists identify specific markers that trigger aggressiveness of liver cancer
By Dross at 2009-10-21 18:21
 

Hepatocellular carcinomaterm (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year. Worldwide, HCC accounts for 632,000 cases with the highest regions being Western Pacific and Africa according to a 2004 World Health Organization (WHO) report.

read more | 1927 reads

Liver Transplant Recipients with Hepatitis B May Need Lifelong Antiviral Treatment
By Dross at 2009-02-27 02:12
 

Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back. A new study shows that they lack cellular immunity against the disease, making recurrence likely if antiviral treatment is withdrawn. These findings are in the March issue of Liver Transplantation, a journal published by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

 

read more | 1753 reads

New study finds advanced liver cancer patients live longer by taking anti-cancer drug sorafenib

Researchers at Mount Sinai School of Medicine in New York have found that sorafenibterm (Nexavartermterm) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug. The findings, published in the July 23rd, 2008 issue of the New England Journal of Medicine, is a significant advance in the management of liver cancer, which is the third cause of cancer death globally, often resulting in death within a year of diagnosis.

"This is the first time that we've had an effective systemic treatment for liver cancer," said Josep Llovet, MD, Director of Research in Liver Cancer at Mount Sinai School of Medicine in New York, and a Professor at the Barcelona Clinic Liver Cancer (BCLC) Group in Barcelona, Spain and lead author of the study. "Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful."

read more | 1898 reads

Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
By admin at 2008-04-14 20:03
 

SAN DIEGO –– Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines. The team is currently designing a trial to test the combination in patients.

Liver cancer is resistant to many chemotherapies and to cell-death inducing agents. Last year, however, the U.S. Food and Drug Administration approved sorafenibterm (Nexavar®) as a treatment for liver cancer after a clinical trial showed that the targeted agent prolonged survival in some patients.

read more | 2 comments | 2136 reads

Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
By Dross at 2008-03-12 19:23
 

Bethesda, MD (March 11, 2008) – A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

Researchers in the study found that while stenting can help reinforce the bile duct to increase liver functionality, the light therapy assisted in attacking the cancer cells directly. The combined therapy led to significant reductions in mortality rates in the year following treatment, compared with stenting treatment alone.

read more | 2395 reads

Discovery of good -- and bad -- liver stem cells raises possibility of new treatment
By Dross at 2008-02-11 00:34
 

Many scientists believe up to 40 percent of liver cancer is caused by stem cells gone wild – master cells in the organ that have lost all growth control. But, despite years spent looking, no one has ever found these liver “cancer stem cells” – or even normal stem cells in the organ. Until now.

In the February 19, 2008 issue of the Proceedings of the National Academy of Sciences (PNAS), researchers at Georgetown University Medical Center report discovering both types of stem cells, and by comparing their genetic “signatures,” they found evidence to suggest that a new type of experimental drug now being tested in other cancers might offer benefit in treating liver cancer.

read more | 2415 reads

Discovery of good -- and bad -- liver stem cells raises possibility of new treatment
By Dross at 2008-02-09 02:32
 

Many scientists believe up to 40 percent of liver cancer is caused by stem cells gone wild – master cells in the organ that have lost all growth control. But, despite years spent looking, no one has ever found these liver “cancer stem cells” – or even normal stem cells in the organ. Until now.

In the February 19, 2008 issue of the Proceedings of the National Academy of Sciences (PNAS), researchers at Georgetown University Medical Center report discovering both types of stem cells, and by comparing their genetic “signatures,” they found evidence to suggest that a new type of experimental drug now being tested in other cancers might offer benefit in treating liver cancer.

read more | 3486 reads

MIT: Why men are more prone to liver cancer
By Dross at 2008-01-17 01:42
 

CAMBRIDGE, Mass.--A fundamental difference in the way males and females respond to chronic liver disease at the genetic level helps explain why men are more prone to liver cancer, according to MIT researchers.

“This is the first genome-wide study that helps explain why there is such a gender effect in a cancer of a nonreproductive organ, where you wouldn't expect to see one,” said Arlin Rogers, an MIT experimental pathologist and lead author of a paper that appeared last month in the journal Cancer Research.

Men develop liver cancer at twice the rate of women in the United States. In other countries, especially in Asia, the rate for men can be eight or 10 times that for women.

read more | 1998 reads

Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
By Dross at 2008-01-15 21:16
 

BOSTON – As the incidence of liver cancer continues to grow-- fueled in large part, by rising rates of hepatitis C infections – so too does the need for tests to help diagnose the disease at an earlier stage. A study appearing in the January 15 issue of Clinical Cancer Research demonstrates that a novel mass-spectrometry based form of proteomic profiling is more accurate than traditional biomarkers in distinguishing liver cancer patients from patients with hepatitis C liver cirrhosis, particularly with regard to identifying patients with small, curable tumors. Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the study could help lead to earlier diagnostic methods – and subsequent treatments -- for liver cancer.

read more | 1 comment | 2443 reads

Moffitt seeking participants for advanced liver cancer study
By Dross at 2008-01-08 22:56
 

Tampa, FL (Jan. 8, 2008) – If you have primary liver cancer that has spread to other organs or is too advanced to be treated by surgery, Moffitt Cancer Center is looking for you. You must not have had prior chemotherapyterm treatment.

Hepatocellular carcinomaterm, or primary liver cancer, is the fifth most common type of tumor. Moffitt is recruiting participants for a phase II study of the oral medication AZD6244, an experimental anti-cancer drug that may stop the growth of cancer cells. The drug is designed to block the pathway of a protein called MEK, which is important for cell survival.

read more | 2440 reads

High-energy ultrasound sharpens view of liver tumors
By Dross at 2008-01-08 21:41
 

DURHAM, N.C. -- A high-energy form of ultrasound imaging developed by researchers at Duke University's Pratt School of Engineering produces pictures of liver tumors that are better than those made with traditional ultrasound, according to results of a clinical study.

The study suggests that the imaging method known as Acoustic Radiation Force Impulse (ARFI) ultrasound might offer a new tool for screening patients at increased risk for liver cancers, according to the researchers. They say it might also play a useful role in guiding biopsy procedures and minimally invasive therapies aimed at destroying cancerous tissues found deep in the abdomen.

read more | 3283 reads

Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study
By Dross at 2007-11-06 04:25
 

Progen Pharmaceuticals Limited (NASDAQ:PGLA) today announced additional data from the Phase 2 liver cancer study of PI-88 completed earlier this year. This data was presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1). As the Phase 2 trial's study period covered 48 weeks from curative surgery, the data analysis described in this presentation was performed to evaluate the treatment's impact when patients with a low risk of experiencing a liver cancer recurrence within twelve months are removed from the analysis population. Patients were removed from the patient population if, based on published prognostic factors, they were considered likely to complete the 12 months of the study without recurrence.

read more | 2233 reads

Tiny radioactive spheres effectively treat cancer that has spread to the liver
By Dross at 2007-10-30 01:41
 

JACKSONVILLE, Fla. − Placing tiny radioactive spheres directly into the liver through its blood supply halted growth of tumors that had spread to the organ in 71 percent of patients tested in a small clinical trial, researchers from Mayo Clinic Jacksonville report.

They say that the technique appears to offer a treatment option for patients who develop multiple tumors in their liver from cancer metastasistermterm.

“Most of these patients don’t have other effective treatment options, because surgery is not possible if there are multiple tumors in their liver,” says the study’s lead investigator, Laura Vallow, M.D. “But with this radiotherapy, no new tumors developed in patients who responded and we find this to be very encouraging.”

read more | 3553 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 04:29 PM.